Drug intelligence / Profile preview

PRT-001

Development stage: Unknown
Lead developer: Particle Therapeutics
Modality: Small Molecules

Overview

PRT-001 is a small molecule drug developed by Particle Therapeutics. It acts as an agonist of the glucagon receptor (GCGR), making it part of the class of GCGR agonists. The primary therapeutic area for PRT-001 is endocrinology and metabolic disease, with its main active indication being hypoglycemia. As a GCGR agonist, PRT-001 works by stimulating the glucagon receptor, which plays a key role in increasing blood glucose levels—making it potentially useful for treating conditions characterized by low blood sugar[1].

Targets

GCGR (Glucagon receptor)

Beyond the preview

Go deeper on PRT-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRT-001.

Explore the full profile